MX2012001282A - Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado. - Google Patents

Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado.

Info

Publication number
MX2012001282A
MX2012001282A MX2012001282A MX2012001282A MX2012001282A MX 2012001282 A MX2012001282 A MX 2012001282A MX 2012001282 A MX2012001282 A MX 2012001282A MX 2012001282 A MX2012001282 A MX 2012001282A MX 2012001282 A MX2012001282 A MX 2012001282A
Authority
MX
Mexico
Prior art keywords
fulvestrant
dose
patients
treatment
study
Prior art date
Application number
MX2012001282A
Other languages
English (en)
Spanish (es)
Inventor
Isaiah William Dimery
Alan Webster
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012001282(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2012001282A publication Critical patent/MX2012001282A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2012001282A 2009-07-27 2010-07-26 Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado. MX2012001282A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0912999.0A GB0912999D0 (en) 2009-07-27 2009-07-27 Method-803
PCT/GB2010/051228 WO2011012885A1 (en) 2009-07-27 2010-07-26 Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer

Publications (1)

Publication Number Publication Date
MX2012001282A true MX2012001282A (es) 2012-06-12

Family

ID=41066853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001282A MX2012001282A (es) 2009-07-27 2010-07-26 Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado.

Country Status (36)

Country Link
US (1) US20120214778A1 (enExample)
EP (1) EP2459199A1 (enExample)
JP (1) JP2013500324A (enExample)
KR (1) KR20120042843A (enExample)
AT (1) AT510868A2 (enExample)
AU (1) AU2010277373A1 (enExample)
BG (1) BG111123A (enExample)
BR (1) BR112012001837A2 (enExample)
CA (1) CA2768286A1 (enExample)
CL (1) CL2012000226A1 (enExample)
CZ (1) CZ201235A3 (enExample)
DE (1) DE112010003084T5 (enExample)
DK (1) DK201270089A (enExample)
EA (1) EA201200190A1 (enExample)
EC (1) ECSP12011629A (enExample)
EE (1) EE201200003A (enExample)
ES (1) ES2393323A1 (enExample)
FI (1) FI20125207L (enExample)
GB (2) GB0912999D0 (enExample)
HR (1) HRP20120084A2 (enExample)
HU (1) HUP1200203A3 (enExample)
IL (1) IL217527A0 (enExample)
IS (1) IS8994A (enExample)
LT (1) LT5953B (enExample)
MX (1) MX2012001282A (enExample)
NO (1) NO20120147A1 (enExample)
PE (1) PE20121177A1 (enExample)
PL (1) PL399129A1 (enExample)
RO (1) RO128705A2 (enExample)
RS (1) RS20120022A1 (enExample)
SE (1) SE1250155A1 (enExample)
SG (1) SG177586A1 (enExample)
SK (1) SK500052012A3 (enExample)
TR (1) TR201200950T1 (enExample)
WO (1) WO2011012885A1 (enExample)
ZA (1) ZA201201406B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP2017515873A (ja) * 2014-05-21 2017-06-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｉ３ｋ阻害剤ピクチリシブでのｐｒ陽性ルミナールａ乳がんの処置方法
US20190147986A1 (en) * 2016-05-17 2019-05-16 Abraxis Bioscience, Llc Methods for assessing neoadjuvant therapies
EP3528818B1 (en) * 2016-10-21 2021-09-15 Crescita Therapeutics Inc. Pharmaceutical compositions
WO2018106444A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
KR102267378B1 (ko) * 2019-09-10 2021-06-21 가천대학교 산학협력단 C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
TR201200950T1 (tr) 2012-09-21
PL399129A1 (pl) 2012-11-19
PE20121177A1 (es) 2012-09-23
CZ201235A3 (cs) 2012-06-27
IL217527A0 (en) 2012-02-29
FI20125207A7 (fi) 2012-02-23
SE1250155A1 (sv) 2012-02-22
EA201200190A1 (ru) 2012-08-30
HRP20120084A2 (hr) 2012-04-30
ES2393323A1 (es) 2012-12-20
RS20120022A1 (sr) 2012-10-31
HUP1200203A3 (en) 2012-12-28
WO2011012885A9 (en) 2011-03-24
GB201201486D0 (en) 2012-03-14
LT5953B (lt) 2013-07-25
WO2011012885A1 (en) 2011-02-03
JP2013500324A (ja) 2013-01-07
GB0912999D0 (en) 2009-09-02
HUP1200203A1 (en) 2012-09-28
EP2459199A1 (en) 2012-06-06
IS8994A (is) 2012-02-24
SG177586A1 (en) 2012-02-28
AU2010277373A1 (en) 2012-02-09
DE112010003084T5 (de) 2012-09-06
BR112012001837A2 (pt) 2016-03-15
EE201200003A (et) 2012-04-16
KR20120042843A (ko) 2012-05-03
CA2768286A1 (en) 2011-02-03
GB2484050A (en) 2012-03-28
CL2012000226A1 (es) 2012-08-31
ECSP12011629A (es) 2012-02-29
SK500052012A3 (sk) 2012-04-03
LT2012006A (lt) 2013-03-25
US20120214778A1 (en) 2012-08-23
BG111123A (bg) 2012-10-31
ZA201201406B (en) 2013-08-28
RO128705A2 (ro) 2013-08-30
AT510868A2 (de) 2012-07-15
FI20125207L (fi) 2012-02-23
NO20120147A1 (no) 2012-04-03
DK201270089A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
JP7745708B2 (ja) 癌を治療するための方法
Paridaens et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
Tabrizi et al. Antiproliferative effect of metformin on the endometrium-a clinical trial
Gershanovich et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer
Croxtall et al. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women
US20240398837A1 (en) Combination Therapy For Prostate Cancer
MX2012001282A (es) Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado.
US20250319084A1 (en) Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
JP5335173B2 (ja) 早期乳癌を有する閉経後の女性の処置のためのアナストロゾールの使用
AU2012100098A4 (en) Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer
US20250186393A1 (en) Treatment of breast cancer with amcenestrant
CN101404988A (zh) 乳腺癌治疗方案
Wlliamson Prostate cancer: treatment options
Pallis et al. Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial
HK40092155A (en) Combination therapy for prostate cancer
Dienger Hormonal therapy
Kothari et al. The Treatment of Advanced Breast Cancer: Focus on Fulvestrant.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal